MetaCap

AirSculpt Technologies (AIRS) vs Starling Oncology (STLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Starling Oncology (STLN) has outperformed AirSculpt Technologies (AIRS) over the past year, losing 4.2% versus a loss of 83.9%. Over five years, STLN leads with a -55.3% price change compared with -95.1% for AIRS. Starling Oncology is the larger company by market cap ($306.0 million vs $43.7 million), about 7.0 times the size.

AirSculpt Technologies converts more of its revenue into profit, with a net margin of -7.7% versus -12.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AIRS-83.86%STLN-4.15%
+136%+20%-96%
Nov 21, 20251 yearNov 20, 2026
AIRS-96.04%STLN-61.09%
+42%-31%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AIRS versus STLN key metrics
MetricAIRSSTLN
Share price$0.5907$3.00
Market cap$43.67M$305.97M
1-day change-9.72%-5.66%
YTD return-70.17%-15.73%
1-year return-83.86%-4.15%
5-year return-95.10%-55.29%
EPS (TTM)$-0.12$-0.28
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$151.82M$502.73M
Revenue growth (YoY)-15.82%+27.79%
Net income (latest FY)$-11.67M$-60.61M
Gross margin59.37%—
Operating margin-7.61%-7.18%
Net margin-7.68%-12.06%
52-week high$5.79$7.13
52-week low$0.516$2.32
Distance from 52-week high-89.80%-57.92%
Analyst consensusnonestrong_buy
Avg. price target upside+661.81%+208.33%
Average volume1.27M2.55M
Shares outstanding73.93M101.99M
Employees330641
SectorHealth CareHealth Care
IndustryMedical/Nursing ServicesMedical/Nursing Services

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Starling Oncology is about 7.0 times larger than AirSculpt Technologies by market value ($305.97M vs $43.67M).
  • STLN has outperformed AIRS by 79.7 percentage points over the past year.
  • Starling Oncology grew revenue faster in its latest fiscal year (+27.79% vs -15.82%).

About AirSculpt Technologies

AIRS stock →

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.

Health Care · Medical/Nursing Services · 330 employees

About Starling Oncology

STLN stock →

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.

Health Care · Medical/Nursing Services · 641 employees

AIRS vs STLN FAQ

Which is bigger, AirSculpt Technologies or Starling Oncology?

Starling Oncology (STLN) is larger, with a market capitalization of $305.97M compared with $43.67M for AirSculpt Technologies (AIRS).

Which stock has performed better over the past year, AIRS or STLN?

STLN returned -4.15% over the past 12 months, compared with -83.86% for AIRS (price return, excluding dividends). Past performance does not predict future results.

Are AirSculpt Technologies and Starling Oncology in the same industry?

Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.

More comparisons